Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | MME | P08473 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15425042 | 0.80 | TACR1 (0.48) | ALDH1A1ATMMAPTCTSBKMT2A | |
| SCHEMBL265561 | 0.79 | ALDH1A1 (0.58) | ALDH1A1HPGDHSD17B10CTSBL3MBTL1 | |
| SCHEMBL265176 | 0.79 | ALDH1A1 (0.58) | ALDH1A1HPGDHSD17B10CTSBL3MBTL1 | |
| SCHEMBL12764099 | 0.79 | ALDH1A1 (0.58) | ALDH1A1HPGDHSD17B10CTSBL3MBTL1 | |
| SCHEMBL4691605 | 0.77 | ALDH1A1 (0.60) | ALDH1A1L3MBTL1MAPK1SLC6A2SLC6A3 | |
| SCHEMBL825025 | 0.77 | MIF (0.39) | ALDH1A1ATMMAPTHPGDHSD17B10 | |
| SCHEMBL13259431 | 0.77 | TACR1 (0.52) | MAPTCTSBMAPK1TDP1 | |
| SCHEMBL18179442 | 0.74 | CYP19A1 (0.52) | ALDH1A1MMELMNA | |
| SCHEMBL846586 | 0.74 | CYP19A1 (0.52) | ALDH1A1MMELMNA | |
| SCHEMBL22930081 | 0.74 | ALDH1A1 (0.59) | ALDH1A1ATMMAPTHPGDCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-27 | — | — | US | disclosed |
| US-20150322048-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-11-12 | — | — | US | disclosed |
| US-20140018389-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018389-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | ALDH1A1 2265/4885ATM 3941/4885MME 2640/4885 |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885ATM 3538/4885MME 1382/4885 |
| US-20150322048-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885ATM 3538/4885MME 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.